Dr. Genoveffa Franchini of the National Cancer Institute will reprise her earlier December 2020 webinar in the Invention Development & Marketing Unit's (IDMU) new, in-house webinar platform. Joseph Conrad will host and facilitate the webinar to a newly sourced audience of potentially interested licensees and collaborators.
This novel HIV vaccine is shown to be highly effective at treating and preventing HIV infection in monkeys, which is due to the deletion of gp120’s V1 region. The absence of the V1 region makes the remaining gp120 V2 region more visible to antibodies and therefore makes the virus visible to the immune system for destruction. Dr. Franchini has also shown that the addition of a RAS activating agent, further enhances the activity of the V1-deleted vaccine. She will also discuss how using a publicly available technology that she also developed (an ALVAC vector) to make the novel V1-deleted vaccine, also enhances the activity of the V1-deleted vaccine. This novel HIV vaccine has the potential to move the current standard of care from: treatment to cure; from suppression to elimination; from lifelong daily treatment to single prime/boost treatment; it has potential to become the new global standard for treating and preventing HIV.